LIVIVO - Suchergebnisse -

Suchergebnis

Treffer 1 - 10 von insgesamt 42

Suchoptionen

Artikel ; Online: Strong immunogenicity & protection in mice with PlaCCine: A COVID-19 DNA vaccine formulated with a functional polymer.

2024 Band 42, Heft 6, Seite(n) 1300–1310

Abstract: DNA- based vaccines have demonstrated the potential as a safe and effective modality. PlaCCine, a DNA-based vaccine approach described subsequently relies on a synthetic DNA delivery system and is independent of virus or device. The synthetic ... ...

Abstract	DNA- based vaccines have demonstrated the potential as a safe and effective modality. PlaCCine, a DNA-based vaccine approach described subsequently relies on a synthetic DNA delivery system and is independent of virus or device. The synthetic functionalized polymer combined with DNA demonstrated stability over 12 months at 4C and for one month at 25C. Transfection efficiency compared to naked DNA increased by 5-15-fold in murine skeletal muscle. Studies of DNA vaccines expressing spike proteins from variants D614G (pVAC15), Delta (pVAC16), or a D614G + Delta combination (pVAC17) were conducted. Mice immunized intramuscular injection (IM) with pVAC15, pVAC16 or pVAC17 formulated with functionalized polymer and adjuvant resulted in induction of spike-specific humoral and cellular responses. Antibody responses were observed after one immunization. And endpoint IgG titers increased to greater than 1x 10
Mesh-Begriff(e)	Mice ; Animals ; COVID-19 Vaccines ; Vaccines, DNA ; COVID-19/prevention & control ; SARS-CoV-2 ; Mice, Transgenic ; Antibodies, Neutralizing ; DNA ; Antibodies, Viral ; Spike Glycoprotein, Coronavirus/genetics ; Immunogenicity, Vaccine
Chemische Substanzen	COVID-19 Vaccines ; Vaccines, DNA ; Antibodies, Neutralizing ; DNA (9007-49-2) ; Antibodies, Viral ; Spike Glycoprotein, Coronavirus ; spike protein, SARS-CoV-2
Sprache	Englisch
Erscheinungsdatum	2024-02-01
Erscheinungsland	Netherlands
Dokumenttyp	Journal Article
ZDB-ID	605674-x
ISSN	1873-2518 ; 0264-410X
ISSN (online)	1873-2518
ISSN	0264-410X
DOI	10.1016/j.vaccine.2024.01.065
Datenquelle	MEDical Literature Analysis and Retrieval System OnLINE

Volltext online

Zugriff für angemeldete ZB MED Nutzerinnen und Nutzer

Zusatzmaterialien

Verfügbar in ZB MED Köln/Königswinter

Zs.A 1930: Hefte anzeigen			Standort: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 458: Hefte anzeigen

Über subito bestellen

Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

Details ▾

Artikel ; Online: A Recombinant Subunit Vaccine Induces a Potent, Broadly Neutralizing, and Durable Antibody Response in Macaques against the SARS-CoV-2 P.1 (Gamma) Variant.

To, Albert / Wong, Teri Ann S / Lieberman, Michael M / Thompson, Karen / Ball, Aquena H / Pessaint, Laurent / Greenhouse, Jack / Daham, Nisrine / Cook, Anthony / Narvaez, Brandon / Flinchbaugh, Zack / Van Ry, Alex / Yalley-Ogunro, Jake / Andersen Elyard, Hanne / Lai, Chih-Yun / Donini, Oreola / Lehrer, Axel T

ACS infectious diseases

2022 Band 8, Heft 4, Seite(n) 825–840

Abstract: FDA-approved and emergency use-authorized vaccines using new mRNA and viral-vector technology are highly effective in preventing moderate to severe disease; however, information on their long-term efficacy and protective breadth against severe acute ... ...

Abstract	FDA-approved and emergency use-authorized vaccines using new mRNA and viral-vector technology are highly effective in preventing moderate to severe disease; however, information on their long-term efficacy and protective breadth against severe acute respiratory syndrome coronavirus 2 variants of concern (VOCs) is currently scarce. Here, we describe the durability and broad-spectrum VOC immunity of a prefusion-stabilized spike (S) protein adjuvanted with liquid or lyophilized CoVaccine HT in cynomolgus macaques. This recombinant subunit vaccine is highly immunogenic and induces robust spike-specific and broadly neutralizing antibody responses effective against circulating VOCs (B.1.351 [Beta], P.1 [Gamma], and B.1.617 [Delta]) for at least three months after the final boost. Protective efficacy and postexposure immunity were evaluated using a heterologous P.1 challenge nearly three months after the last immunization. Our results indicate that while immunization with both high and low S doses shorten and reduce viral loads in the upper and lower respiratory tract, a higher antigen dose is required to provide durable protection against disease as vaccine immunity wanes. Histologically, P.1 infection causes similar COVID-19-like lung pathology as seen with early pandemic isolates. Postchallenge IgG concentrations were restored to peak immunity levels, and vaccine-matched and cross-variant neutralizing antibodies were significantly elevated in immunized macaques indicating an efficient anamnestic response. Only low levels of P.1-specific neutralizing antibodies with limited breadth were observed in control (nonvaccinated but challenged) macaques, suggesting that natural infection may not prevent reinfection by other VOCs. Overall, these results demonstrate that a properly dosed and adjuvanted recombinant subunit vaccine can provide protective immunity against circulating VOCs for at least three months.
Mesh-Begriff(e)	Adjuvants, Immunologic ; Animals ; Antibodies, Neutralizing ; Antibodies, Viral ; Antibody Formation ; COVID-19/prevention & control ; COVID-19 Vaccines ; Humans ; Macaca ; SARS-CoV-2 ; Vaccines, Subunit
Chemische Substanzen	Adjuvants, Immunologic ; Antibodies, Neutralizing ; Antibodies, Viral ; COVID-19 Vaccines ; Vaccines, Subunit
Sprache	Englisch
Erscheinungsdatum	2022-03-09
Erscheinungsland	United States
Dokumenttyp	Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
ISSN	2373-8227
ISSN (online)	2373-8227
DOI	10.1021/acsinfecdis.1c00600
Datenquelle	MEDical Literature Analysis and Retrieval System OnLINE

Zusatzmaterialien

Über subito bestellen

Fernleihe an ZB MED

Sie können sich den gewünschten Titel als lokale Nutzerin oder lokaler Nutzer von ZB MED direkt an den Standort Köln schicken lassen.

Details ▾
- Kostenpflichtig bestellen

Artikel ; Online: One dose of COVID-19 nanoparticle vaccine REVC-128 protects against SARS-CoV-2 challenge at two weeks post-immunization.

Gu, Maggie / Torres, Jonathan L / Li, Yijia / Van Ry, Alex / Greenhouse, Jack / Wallace, Shannon / Chiang, Chi-I / Pessaint, Laurent / Jackson, Abigail M / Porto, Maciel / Kar, Swagata / Li, Yuxing / Ward, Andrew B / Wang, Yimeng

Emerging microbes & infections

2021 Band 10, Heft 1, Seite(n) 2016–2029

Abstract: ... ...

Abstract	ABSTRACT
Mesh-Begriff(e)	Animals ; Antibodies, Neutralizing ; Antibodies, Viral/blood ; Antibody Formation ; COVID-19/prevention & control ; COVID-19 Vaccines/administration & dosage ; COVID-19 Vaccines/immunology ; Cricetinae ; Humans ; Immunization ; Immunization Schedule ; Immunogenicity, Vaccine ; Mesocricetus ; Mice ; Nanoparticles/chemistry ; SARS-CoV-2 ; Spike Glycoprotein, Coronavirus ; Vaccination ; Viral Load
Chemische Substanzen	Antibodies, Neutralizing ; Antibodies, Viral ; COVID-19 Vaccines ; Spike Glycoprotein, Coronavirus
Sprache	Englisch
Erscheinungsdatum	2021-10-12
Erscheinungsland	United States
Dokumenttyp	Journal Article
ZDB-ID	2681359-2
ISSN	2222-1751 ; 2222-1751
ISSN (online)	2222-1751
ISSN	2222-1751
DOI	10.1080/22221751.2021.1994354
Datenquelle	MEDical Literature Analysis and Retrieval System OnLINE

Zusatzmaterialien

Über subito bestellen

Details ▾
- Kostenpflichtig bestellen

Artikel ; Online: Defining the determinants of protection against SARS-CoV-2 infection and viral control in a dose-down Ad26.CoV2.S vaccine study in nonhuman primates.

Zhu, Daniel Y / Gorman, Matthew J / Yuan, Dansu / Yu, Jingyou / Mercado, Noe B / McMahan, Katherine / Borducchi, Erica N / Lifton, Michelle / Liu, Jinyan / Nampanya, Felix / Patel, Shivani / Peter, Lauren / Tostanoski, Lisa H / Pessaint, Laurent / Van Ry, Alex / Finneyfrock, Brad / Velasco, Jason / Teow, Elyse / Brown, Renita /

Cook, Anthony / Andersen, Hanne / Lewis, Mark G / Lauffenburger, Douglas A / Barouch, Dan H / Alter, Galit

PLoS biology

2022 Band 20, Heft 5, Seite(n) e3001609

Abstract: Despite the rapid creation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) vaccines, the precise correlates of immunity against severe Coronavirus Disease 2019 (COVID-19) are still unknown. Neutralizing antibodies represent a robust ... ...

Abstract	Despite the rapid creation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) vaccines, the precise correlates of immunity against severe Coronavirus Disease 2019 (COVID-19) are still unknown. Neutralizing antibodies represent a robust surrogate of protection in early Phase III studies, but vaccines provide protection prior to the evolution of neutralization, vaccines provide protection against variants that evade neutralization, and vaccines continue to provide protection against disease severity in the setting of waning neutralizing titers. Thus, in this study, using an Ad26.CoV2.S dose-down approach in nonhuman primates (NHPs), the role of neutralization, Fc effector function, and T-cell immunity were collectively probed against infection as well as against viral control. While dosing-down minimally impacted neutralizing and binding antibody titers, Fc receptor binding and functional antibody levels were induced in a highly dose-dependent manner. Neutralizing antibody and Fc receptor binding titers, but minimally T cells, were linked to the prevention of transmission. Conversely, Fc receptor binding/function and T cells were linked to antiviral control, with a minimal role for neutralization. These data point to dichotomous roles of neutralization and T-cell function in protection against transmission and disease severity and a continuous role for Fc effector function as a correlate of immunity key to halting and controlling SARS-CoV-2 and emerging variants.
Mesh-Begriff(e)	Ad26COVS1 ; Animals ; Antibodies, Neutralizing ; Antibodies, Viral ; COVID-19/prevention & control ; COVID-19 Vaccines ; Humans ; Primates ; Receptors, Fc ; SARS-CoV-2 ; Spike Glycoprotein, Coronavirus
Chemische Substanzen	Ad26COVS1 (JT2NS6183B) ; Antibodies, Neutralizing ; Antibodies, Viral ; COVID-19 Vaccines ; Receptors, Fc ; Spike Glycoprotein, Coronavirus ; spike protein, SARS-CoV-2
Sprache	Englisch
Erscheinungsdatum	2022-05-05
Erscheinungsland	United States
Dokumenttyp	Journal Article ; Research Support, N.I.H., Extramural
ZDB-ID	2126776-5
ISSN	1545-7885 ; 1544-9173
ISSN (online)	1545-7885
ISSN	1544-9173
DOI	10.1371/journal.pbio.3001609
Datenquelle	MEDical Literature Analysis and Retrieval System OnLINE

Zusatzmaterialien

Verfügbar in ZB MED Köln/Königswinter

Zs.A 6193: Hefte anzeigen

Standort:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Über subito bestellen

Details ▾
- Im ZB MED-Bestand
- Kostenpflichtig bestellen

Artikel: RBD-based high affinity ACE2 antagonist limits SARS-CoV-2 replication in upper and lower airways.

Gagne, Matthew / Flynn, Barbara J / Honeycutt, Christopher Cole / Flebbe, Dillon R / Andrew, Shayne F / Provost, Samantha J / McCormick, Lauren / Van Ry, Alex / McCarthy, Elizabeth / Todd, John-Paul M / Bao, Saran / Teng, I-Ting / Marciano, Shir / Rudich, Yinon / Li, Chunlin / Pessaint, Laurent / Dodson, Alan / Cook, Anthony / Lewis, Mark G /

Andersen, Hanne / Zahradník, Jiří / Nason, Martha C / Foulds, Kathryn E / Kwong, Peter D / Roederer, Mario / Schreiber, Gideon / Seder, Robert A / Douek, Daniel C

bioRxiv : the preprint server for biology

2023

Abstract: SARS-CoV-2 has the capacity to evolve mutations to escape vaccine-and infection-acquired immunity and antiviral drugs. A variant-agnostic therapeutic agent that protects against severe disease without putting selective pressure on the virus would thus be ...

Abstract	SARS-CoV-2 has the capacity to evolve mutations to escape vaccine-and infection-acquired immunity and antiviral drugs. A variant-agnostic therapeutic agent that protects against severe disease without putting selective pressure on the virus would thus be a valuable biomedical tool. Here, we challenged rhesus macaques with SARS-CoV-2 Delta and simultaneously treated them with aerosolized RBD-62, a protein developed through multiple rounds of
Sprache	Englisch
Erscheinungsdatum	2023-06-12
Erscheinungsland	United States
Dokumenttyp	Preprint
DOI	10.1101/2023.06.09.544432
Datenquelle	MEDical Literature Analysis and Retrieval System OnLINE

Zusatzmaterialien

Fernleihe an ZB MED

Sie können sich den gewünschten Titel als lokale Nutzerin oder lokaler Nutzer von ZB MED direkt an den Standort Köln schicken lassen.

Details ▾

Artikel ; Online: Strong immunogenicity & protection in mice with PlaCCine: A COVID-19 DNA vaccine formulated with a functional polymer

bioRxiv

Abstract	DNA- based vaccines have demonstrated the potential as a safe and effective modality. PlaCCine, a DNA-based vaccine approach described subsequently relies on a synthetic DNA delivery system and is independent of virus or device. The synthetic functionalized polymer combined with DNA demonstrated stability over 12 months at 4C and for one month at 25C. Transfection efficiency compared to naked DNA increased by 5-15-fold in murine skeletal muscle. Studies of DNA vaccines expressing spike proteins from variants D614G (pVAC15), Delta (pVAC16), or a D614G + Delta combination (pVAC17) were conducted. Mice immunized intramuscular injection (IM) with pVAC15, pVAC16 or pVAC17 formulated with functionalized polymer and adjuvant resulted in induction of spike-specific humoral and cellular responses. Antibody responses were observed after one immunization. And endpoint IgG titers increased to greater than 1x 105 two weeks after the second injection. Neutralizing antibodies as determined by a pseudovirus competition assay were observed following vaccination with pVAC15, pVAC16 or pVAC17. Spike specific T cell immune responses were also observed following vaccination and flow cytometry analysis demonstrated the cellular immune responses included both CD4 and CD8 spike specific T cells. The immune responses in vaccinated mice were maintained for up to 14 months after vaccination. In an immunization and challenge study of K18 hACE2 transgenic mice pVAC15, pVAC16 and pVAC17 induced immune responses lead to decreased lung viral loads by greater than 90% along with improved clinical score. These findings suggest that PlaCCine DNA vaccines are effective and stable and further development against emerging SARS-CoV-2 variants is warranted.
Schlagwörter	covid19
Sprache	Englisch
Erscheinungsdatum	2023-08-02
Verlag	Cold Spring Harbor Laboratory
Dokumenttyp	Artikel ; Online
DOI	10.1101/2023.08.01.551509
Datenquelle	COVID19

Volltext online

Fernleihe an ZB MED

Sie können sich den gewünschten Titel als lokale Nutzerin oder lokaler Nutzer von ZB MED direkt an den Standort Köln schicken lassen.

Artikel ; Online: Protein Vaccine Induces a Durable, More Broadly Neutralizing Antibody Response in Macaques than Natural Infection with SARS-CoV-2 P.1

To, Albert / Wong, Teri Ann S / Lieberman, Michael M / Thompson, Karen S / Pessaint, Laurent / Greenhouse, Jack / Daham, Nisrine / Cook, Anthony / Narvaez, Brandon / Flinchbaugh, Zack / Van Ry, Alex / Yalley-Ogunro, Jake / Andersen, Hanne / Lai, Chih-Yun / Donini, Oreola / Lehrer, Axel T

bioRxiv

Abstract: FDA-approved and Emergency Use Authorized (EUA) vaccines using new mRNA and viral-vector technology are highly effective in preventing moderate to severe disease, however, information on their long-term efficacy and protective breadth against SARS-CoV-2 ... ...

Abstract	FDA-approved and Emergency Use Authorized (EUA) vaccines using new mRNA and viral-vector technology are highly effective in preventing moderate to severe disease, however, information on their long-term efficacy and protective breadth against SARS-CoV-2 Variants of Concern (VOCs) is currently scarce. Here we describe the durability and broad-spectrum VOC immunity of a prefusion-stabilized spike (S) protein adjuvanted with liquid or lyophilized CoVaccine HTTM in cynomolgus macaques. This recombinant subunit vaccine is highly immunogenic and induces robust spike-specific and broadly neutralizing antibody responses effective against circulating VOCs (B.1.351 [Beta], P.1 [Gamma], B.1.617 [Delta]) for at least 3 months after the final boost. Protective efficacy and post-exposure immunity were evaluated using a heterologous P.1 challenge nearly 3 months after the last immunization. Our results indicate that while immunization with both high and low S doses shorten and reduce viral loads in the upper and lower respiratory tract, a higher antigen dose is required to provide durable protection against disease as vaccine immunity wanes. Histologically, P.1 infection causes similar COVID-19-like lung pathology as seen with early pandemic isolates. Post-challenge IgG concentrations were restored to peak immunity levels and vaccine-matched and cross-variant neutralizing antibodies were significantly elevated in immunized macaques indicating an efficient anamnestic response. Only low levels of P.1-specific neutralizing antibodies with limited breadth were observed in control (non-vaccinated but challenged) macaques suggesting that natural infection may not prevent reinfection by other VOCs. Overall, these results demonstrate that a properly dosed and adjuvanted recombinant subunit vaccine can provide long-lasting and protective immunity against circulating VOCs.
Schlagwörter	covid19
Sprache	Englisch
Erscheinungsdatum	2021-09-25
Verlag	Cold Spring Harbor Laboratory
Dokumenttyp	Artikel ; Online
DOI	10.1101/2021.09.24.461759
Datenquelle	COVID19

Volltext online

Fernleihe an ZB MED

Sie können sich den gewünschten Titel als lokale Nutzerin oder lokaler Nutzer von ZB MED direkt an den Standort Köln schicken lassen.

Artikel: Low-dose Ad26.COV2.S protection against SARS-CoV-2 challenge in rhesus macaques

He, Xuan / Chandrashekar, Abishek / Zahn, Roland / Wegmann, Frank / Yu, Jingyou / Mercado, Noe B. / McMahan, Katherine / Martinot, Amanda J. / Piedra-Mora, Cesar / Beecy, Sidney / Ducat, Sarah / Chamanza, Ronnie / Huber, Sietske Rosendahl / van Heerden, Marjolein / van der Fits, Leslie / Borducchi, Erica N. / Lifton, Michelle / Liu, Jinyan / Nampanya, Felix /

Patel, Shivani / Peter, Lauren / Tostanoski, Lisa H. / Pessaint, Laurent / Van Ry, Alex / Finneyfrock, Brad / Velasco, Jason / Teow, Elyse / Brown, Renita / Cook, Anthony / Andersen, Hanne / Lewis, Mark G. / Schuitemaker, Hanneke / Barouch, Dan H.

Cell. 2021 June 24, v. 184, no. 13

2021

Abstract: We previously reported that a single immunization with an adenovirus serotype 26 (Ad26)-vector-based vaccine expressing an optimized SARS-CoV-2 spike (Ad26.COV2.S) protected rhesus macaques against SARS-CoV-2 challenge. To evaluate reduced doses of Ad26 ... ...

Abstract	We previously reported that a single immunization with an adenovirus serotype 26 (Ad26)-vector-based vaccine expressing an optimized SARS-CoV-2 spike (Ad26.COV2.S) protected rhesus macaques against SARS-CoV-2 challenge. To evaluate reduced doses of Ad26.COV2.S, 30 rhesus macaques were immunized once with 1 × 10¹¹, 5 × 10¹⁰, 1.125 × 10¹⁰, or 2 × 10⁹ viral particles (vp) Ad26.COV2.S or sham and were challenged with SARS-CoV-2. Vaccine doses as low as 2 × 10⁹ vp provided robust protection in bronchoalveolar lavage, whereas doses of 1.125 × 10¹⁰ vp were required for protection in nasal swabs. Activated memory B cells and binding or neutralizing antibody titers following vaccination correlated with protective efficacy. At suboptimal vaccine doses, viral breakthrough was observed but did not show enhancement of disease. These data demonstrate that a single immunization with relatively low dose of Ad26.COV2.S effectively protected against SARS-CoV-2 challenge in rhesus macaques, although a higher vaccine dose may be required for protection in the upper respiratory tract.
Schlagwörter	Severe acute respiratory syndrome coronavirus 2 ; memory ; nose ; serotypes ; vaccination ; vaccines
Sprache	Englisch
Erscheinungsverlauf	2021-0624
Umfang	p. 3467-3473.e11.
Erscheinungsort	Elsevier Inc.
Dokumenttyp	Artikel
ZDB-ID	187009-9
ISSN	1097-4172 ; 0092-8674
ISSN (online)	1097-4172
ISSN	0092-8674
DOI	10.1016/j.cell.2021.05.040
Datenquelle	NAL Katalog (AGRICOLA)

Volltext online

Zugriff für angemeldete ZB MED Nutzerinnen und Nutzer

Zusatzmaterialien

Verfügbar in ZB MED Bonn

Z 75/702: Hefte anzeigen
Z 93: Hefte anzeigen

Über subito bestellen

Fernleihe an ZB MED

Sie können sich den gewünschten Titel als lokale Nutzerin oder lokaler Nutzer von ZB MED direkt an den Standort Köln schicken lassen.

Details ▾

Artikel: Vaccine Protection Against the SARS-CoV-2 Omicron Variant in Macaques.

Chandrashekar, Abishek / Yu, Jingyou / McMahan, Katherine / Jacob-Dolan, Catherine / Liu, Jinyan / He, Xuan / Hope, David / Anioke, Tochi / Barrett, Julia / Chung, Benjamin / Hachmann, Nicole P / Lifton, Michelle / Miller, Jessica / Powers, Olivia / Sciacca, Michaela / Sellers, Daniel / Siamatu, Mazuba / Surve, Nehalee / VanWyk, Haley /

Wan, Huahua / Wu, Cindy / Pessaint, Laurent / Valentin, Daniel / Van Ry, Alex / Muench, Jeanne / Boursiquot, Mona / Cook, Anthony / Velasco, Jason / Teow, Elyse / Boon, Adrianus C M / Suthar, Mehul S / Jain, Neharika / Martinot, Amanda J / Lewis, Mark G / Andersen, Hanne / Barouch, Dan H

bioRxiv : the preprint server for biology

2022

Abstract: Background: The rapid spread of the SARS-CoV-2 Omicron (B.1.1.529) variant, including in highly vaccinated populations, has raised important questions about the efficacy of current vaccines. Immune correlates of vaccine protection against Omicron are ... ...

Abstract	Background: The rapid spread of the SARS-CoV-2 Omicron (B.1.1.529) variant, including in highly vaccinated populations, has raised important questions about the efficacy of current vaccines. Immune correlates of vaccine protection against Omicron are not known. Methods: 30 cynomolgus macaques were immunized with homologous and heterologous prime-boost regimens with the mRNA-based BNT162b2 vaccine and the adenovirus vector-based Ad26.COV2.S vaccine. Following vaccination, animals were challenged with the SARS-CoV-2 Omicron variant by the intranasal and intratracheal routes. Results: Omicron neutralizing antibodies were observed following the boost immunization and were higher in animals that received BNT162b2, whereas Omicron CD8+ T cell responses were higher in animals that received Ad26.COV2.S. Following Omicron challenge, sham controls showed more prolonged virus in nasal swabs than in bronchoalveolar lavage. Vaccinated macaques demonstrated rapid control of virus in bronchoalveolar lavage, and most vaccinated animals also controlled virus in nasal swabs, showing that current vaccines provide substantial protection against Omicron in this model. However, vaccinated animals that had moderate levels of Omicron neutralizing antibodies but negligible Omicron CD8+ T cell responses failed to control virus in the upper respiratory tract. Virologic control correlated with both antibody and T cell responses. Conclusions: BNT162b2 and Ad26.COV2.S provided robust protection against high-dose challenge with the SARS-CoV-2 Omicron variant in macaques. Protection against this highly mutated SARS-CoV-2 variant correlated with both humoral and cellular immune responses.
Sprache	Englisch
Erscheinungsdatum	2022-02-07
Erscheinungsland	United States
Dokumenttyp	Preprint
DOI	10.1101/2022.02.06.479285
Datenquelle	MEDical Literature Analysis and Retrieval System OnLINE

Zusatzmaterialien

Fernleihe an ZB MED

Sie können sich den gewünschten Titel als lokale Nutzerin oder lokaler Nutzer von ZB MED direkt an den Standort Köln schicken lassen.

Details ▾

Artikel ; Online: Vaccine protection against the SARS-CoV-2 Omicron variant in macaques.

Cell

2022 Band 185, Heft 9, Seite(n) 1549–1555.e11

Abstract: The rapid spread of the SARS-CoV-2 Omicron (B.1.1.529) variant, including in highly vaccinated populations, has raised important questions about the efficacy of current vaccines. In this study, we show that the mRNA-based BNT162b2 vaccine and the ... ...

Abstract	The rapid spread of the SARS-CoV-2 Omicron (B.1.1.529) variant, including in highly vaccinated populations, has raised important questions about the efficacy of current vaccines. In this study, we show that the mRNA-based BNT162b2 vaccine and the adenovirus-vector-based Ad26.COV2.S vaccine provide robust protection against high-dose challenge with the SARS-CoV-2 Omicron variant in cynomolgus macaques. We vaccinated 30 macaques with homologous and heterologous prime-boost regimens with BNT162b2 and Ad26.COV2.S. Following Omicron challenge, vaccinated macaques demonstrated rapid control of virus in bronchoalveolar lavage, and most vaccinated animals also controlled virus in nasal swabs. However, 4 vaccinated animals that had moderate Omicron-neutralizing antibody titers and undetectable Omicron CD8+ T cell responses failed to control virus in the upper respiratory tract. Moreover, virologic control correlated with both antibody and T cell responses. These data suggest that both humoral and cellular immune responses contribute to vaccine protection against a highly mutated SARS-CoV-2 variant.
Mesh-Begriff(e)	Ad26COVS1/administration & dosage ; Ad26COVS1/immunology ; Animals ; Antibodies, Neutralizing ; Antibodies, Viral ; BNT162 Vaccine/administration & dosage ; BNT162 Vaccine/immunology ; COVID-19/immunology ; COVID-19/prevention & control ; Macaca ; SARS-CoV-2 ; T-Lymphocytes/immunology
Chemische Substanzen	Ad26COVS1 (JT2NS6183B) ; Antibodies, Neutralizing ; Antibodies, Viral ; BNT162 Vaccine (N38TVC63NU)
Sprache	Englisch
Erscheinungsdatum	2022-03-17
Erscheinungsland	United States
Dokumenttyp	Journal Article ; Research Support, Non-U.S. Gov't ; Research Support, N.I.H., Extramural
ZDB-ID	187009-9
ISSN	1097-4172 ; 0092-8674
ISSN (online)	1097-4172
ISSN	0092-8674
DOI	10.1016/j.cell.2022.03.024
Datenquelle	MEDical Literature Analysis and Retrieval System OnLINE

Volltext online

Zugriff für angemeldete ZB MED Nutzerinnen und Nutzer

Zusatzmaterialien

Verfügbar in ZB MED Köln/Königswinter

Zs.A 1167: Hefte anzeigen			Standort: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MG 58: Hefte anzeigen

Über subito bestellen

Details ▾

Zum Seitenanfang

Ihre letzten Suchen

Volltext online

Zusatzmaterialien

Kategorien

Verfügbar in ZB MED Köln/Königswinter

Über subito bestellen

Zusatzmaterialien

Kategorien

Über subito bestellen

Fernleihe an ZB MED

Zusatzmaterialien

Kategorien

Über subito bestellen

Zusatzmaterialien

Kategorien

Verfügbar in ZB MED Köln/Königswinter

Über subito bestellen

Zusatzmaterialien

Kategorien

Fernleihe an ZB MED

Volltext online

Kategorien

Fernleihe an ZB MED

Volltext online

Kategorien

Fernleihe an ZB MED

Volltext online

Zusatzmaterialien

Kategorien

Verfügbar in ZB MED Bonn

Über subito bestellen

Fernleihe an ZB MED

Zusatzmaterialien

Kategorien

Fernleihe an ZB MED

Volltext online

Zusatzmaterialien

Kategorien

Verfügbar in ZB MED Köln/Königswinter

Über subito bestellen